vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and OFG BANCORP (OFG). Click either name above to swap in a different company.
OFG BANCORP is the larger business by last-quarter revenue ($184.3M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 0.9%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 2.8%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
OFG Bancorp, founded in 1964, is the financial holding company for Oriental Bank, located in San Juan, Puerto Rico. OFG offers a wide range of retail and commercial banking, lending and wealth management products, services and technology, primarily in Puerto Rico and the U.S. Virgin Islands through its principal subsidiaries: Oriental Bank, Oriental Financial Services LLC, and Oriental Insurance LLC. Its headquarters are located at Oriental Center, 254 Muñoz Rivera Avenue, San Juan, PR 00918....
ESPR vs OFG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $184.3M |
| Net Profit | — | $55.9M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 25.7% |
| Net Margin | — | 30.3% |
| Revenue YoY | 143.7% | 0.9% |
| Net Profit YoY | — | 11.0% |
| EPS (diluted) | $0.32 | $1.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $184.3M | ||
| Q3 25 | $87.3M | $186.2M | ||
| Q2 25 | $82.4M | $182.4M | ||
| Q1 25 | $65.0M | $178.6M | ||
| Q4 24 | $69.1M | $182.7M | ||
| Q3 24 | $51.6M | $174.7M | ||
| Q2 24 | $73.8M | $179.8M | ||
| Q1 24 | $137.7M | $174.4M |
| Q4 25 | — | $55.9M | ||
| Q3 25 | $-31.3M | $51.8M | ||
| Q2 25 | $-12.7M | $51.8M | ||
| Q1 25 | $-40.5M | $45.6M | ||
| Q4 24 | — | $50.3M | ||
| Q3 24 | $-29.5M | $47.0M | ||
| Q2 24 | $-61.9M | $51.1M | ||
| Q1 24 | $61.0M | $49.7M |
| Q4 25 | 50.6% | 25.7% | ||
| Q3 25 | -11.4% | 33.0% | ||
| Q2 25 | 8.6% | 36.1% | ||
| Q1 25 | -34.0% | 33.3% | ||
| Q4 24 | -6.4% | 28.9% | ||
| Q3 24 | -31.0% | 35.4% | ||
| Q2 24 | 3.5% | 39.6% | ||
| Q1 24 | 52.5% | 38.9% |
| Q4 25 | — | 30.3% | ||
| Q3 25 | -35.9% | 27.8% | ||
| Q2 25 | -15.4% | 28.4% | ||
| Q1 25 | -62.2% | 25.5% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | -57.2% | 26.9% | ||
| Q2 24 | -83.9% | 28.4% | ||
| Q1 24 | 44.3% | 28.5% |
| Q4 25 | $0.32 | $1.27 | ||
| Q3 25 | $-0.16 | $1.16 | ||
| Q2 25 | $-0.06 | $1.15 | ||
| Q1 25 | $-0.21 | $1.00 | ||
| Q4 24 | $-0.14 | $1.10 | ||
| Q3 24 | $-0.15 | $1.00 | ||
| Q2 24 | $-0.33 | $1.08 | ||
| Q1 24 | $0.34 | $1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $1.0B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.4B |
| Total Assets | $465.9M | $12.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $1.0B | ||
| Q3 25 | $92.4M | $740.3M | ||
| Q2 25 | $86.1M | $851.8M | ||
| Q1 25 | $114.6M | $710.6M | ||
| Q4 24 | $144.8M | $591.1M | ||
| Q3 24 | $144.7M | $680.6M | ||
| Q2 24 | $189.3M | $740.4M | ||
| Q1 24 | $226.6M | $754.4M |
| Q4 25 | $-302.0M | $1.4B | ||
| Q3 25 | $-451.4M | $1.4B | ||
| Q2 25 | $-433.5M | $1.3B | ||
| Q1 25 | $-426.2M | $1.3B | ||
| Q4 24 | $-388.7M | $1.3B | ||
| Q3 24 | $-370.2M | $1.3B | ||
| Q2 24 | $-344.2M | $1.2B | ||
| Q1 24 | $-294.3M | $1.2B |
| Q4 25 | $465.9M | $12.5B | ||
| Q3 25 | $364.0M | $12.2B | ||
| Q2 25 | $347.1M | $12.2B | ||
| Q1 25 | $324.0M | $11.7B | ||
| Q4 24 | $343.8M | $11.5B | ||
| Q3 24 | $314.1M | $11.5B | ||
| Q2 24 | $352.3M | $11.3B | ||
| Q1 24 | $373.1M | $11.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $217.7M |
| Free Cash FlowOCF − Capex | — | $199.3M |
| FCF MarginFCF / Revenue | — | 108.1% |
| Capex IntensityCapex / Revenue | 0.0% | 10.0% |
| Cash ConversionOCF / Net Profit | — | 3.90× |
| TTM Free Cash FlowTrailing 4 quarters | — | $345.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $217.7M | ||
| Q3 25 | $-4.3M | $39.5M | ||
| Q2 25 | $-31.4M | $35.9M | ||
| Q1 25 | $-22.6M | $83.1M | ||
| Q4 24 | $-35.0M | $252.5M | ||
| Q3 24 | $-35.3M | $58.1M | ||
| Q2 24 | $-7.2M | $95.1M | ||
| Q1 24 | $53.8M | $61.0M |
| Q4 25 | — | $199.3M | ||
| Q3 25 | — | $35.5M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $78.7M | ||
| Q4 24 | — | $231.2M | ||
| Q3 24 | $-35.5M | $51.8M | ||
| Q2 24 | $-7.3M | $90.4M | ||
| Q1 24 | $53.8M | $54.8M |
| Q4 25 | — | 108.1% | ||
| Q3 25 | — | 19.1% | ||
| Q2 25 | — | 17.4% | ||
| Q1 25 | — | 44.1% | ||
| Q4 24 | — | 126.5% | ||
| Q3 24 | -68.7% | 29.6% | ||
| Q2 24 | -9.9% | 50.3% | ||
| Q1 24 | 39.0% | 31.4% |
| Q4 25 | 0.0% | 10.0% | ||
| Q3 25 | 0.0% | 2.1% | ||
| Q2 25 | 0.0% | 2.3% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.0% | 11.7% | ||
| Q3 24 | 0.3% | 3.6% | ||
| Q2 24 | 0.1% | 2.6% | ||
| Q1 24 | 0.1% | 3.5% |
| Q4 25 | — | 3.90× | ||
| Q3 25 | — | 0.76× | ||
| Q2 25 | — | 0.69× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 5.02× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | 0.88× | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
OFG
Segment breakdown not available.
